Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

Autor: Annegret Pelchen-Matthews, Jakob Friis Larsen, Leah Shepherd, Josip Begovac, Karen Pedersen, Stéphane De Wit, Andrzej Horban, Elzbieta Jablonowska, Margaret Johnson, Irina Khromova, Marcelo H. Losso, Lars N. Nielsen, Anna Lisa Ridolfo, Brigitte Schmied, Christoph Stephan, Israel Yust, Lloyd Curtis, Vani Vannappagari, Leigh Ragone, Ashley Roen, Dorthe Raben, Ole Kirk, Lars Peters, Amanda Mocroft, for the EuroSIDA Study Group

Publikováno v: HIV Research & Clinical Practice, Vol 22, Iss 6, Pp 160-168 (2021)

Background: Hypersensitivity reaction (HSR) and hepatotoxicity are rare, but potentially serious side-effects of antiretroviral use. Objective: To investigate discontinuations due to HSR, hepatotoxicity or other reasons among users of dolutegravir (D

Externí odkaz: https://doaj.org/article/19ba791aac3342e2ac27b1f0aef3c856

A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study

Autor: Gisela Leierer, Armin Rieger, Brigitte Schmied, Mario Sarcletti, Angela Öllinger, Elmar Wallner, Alexander Egle, Manfred Kanatschnig, Alexander Zoufaly, Michele Atzl, Michaela Rappold, Ziad El-Khatib, Bruno Ledergerber, Robert Zangerle, on behalf of the Austrian HIV Cohort Study Group

Publikováno v: International Journal of Environmental Research and Public Health
International Journal of Environmental Research and Public Health; Volume 18; Issue 23; Pages: 12532
International Journal of Environmental Research and Public Health, Vol 18, Iss 12532, p 12532 (2021)

(1) Objective: To investigate changes in mortality rates and predictors of all-cause mortality as well as specific causes of death over time among HIV-positive individuals in the combination antiretroviral therapy (cART) era. (2) Methods: We analyzed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0159c0d41af2c42fc328771bf37156
https://doi.org/10.5167/uzh-210776

Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations

Autor: Jelena Smidt, Elena Kuzovatova, Nikoloz Chkhartishvili, Kamilla Laut, Eric Florence, Dzmitry Paduta, Dalibor Sedláček, Roxana Radoi, Brigitte Schmied, Gerd Fätkenheuer, Janos Szlavik, Matti Ristola, Fiona Mulcahy, Patrick Schmid, Leah Shepherd, Josip Begovac, Magnus Gottfredsson, Pere Domingo, Jens D Lundgren, Ole Kirk, Brygida Knysz, Amanda Mocroft

Publikováno v: Laut, K G, Shepherd, L, Gottfredsson, M, Sedlacek, D, Knysz, B, Begovac, J, Radoi, R, Schmied, B, Chkhartishvili, N, Florence, E, Ristola, M, Fätkenheuer, G, Mulcahy, F, Schmid, P, Kuzovatova, E, Paduta, D, Smidt, J, Domingo, P, Szlávik, J, Lundgren, J, Mocroft, A, Kirk, O & EuroSIDA Study Group 2018, ' Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations ', AIDS (London, England), vol. 32, no. 18, pp. 2807-2819 . https://doi.org/10.1097/QAD.0000000000002035

Objectives: We assessed differences in antiretroviral treatment (ART) coverage and virological suppression across three HIV key populations, as defined by self-reported HIV transmission category: sex between men, injection drug use (IDU) and heterose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9fe07dda086d59b27922bbc33c005c7
https://pure.au.dk/portal/da/publications/variation-in-antiretroviral-treatment-coverage-and-virological-suppression-among-three-hiv-key-populations(9ba56ebe-ab90-47d8-9563-5270ccd7d5db).html

HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension

Autor: Brigitte Schmied, Markus Peck-Radosavljevic, Thomas Reiberger, Arnulf Ferlitsch, Alfred Gangl, Armin Rieger, F Breitenecker, Wolfgang Sieghart, A. Kreil

Publikováno v: Journal of Viral Hepatitis. 17:400-409

Patients co-infected with the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV) are fraught with a rapid fibrosis progression rate and with complications of portal hypertension (PHT) We aimed to assess the influence of immune functio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::350ac6ab1d3b96116b697d463fec5672
https://doi.org/10.1111/j.1365-2893.2009.01197.x

A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin

Autor: Berit A. Payer, Arnulf Ferlitsch, Vienna Hepatic Hemodynamic Lab, F Breitenecker, Thomas Reiberger, Armin Rieger, Wolfgang Sieghart, Michael Trauner, Markus Peck-Radosavljevic, Brigitte Schmied, Maximilian C. Aichelburg

Publikováno v: Antiviral therapy. 17(7)

Background Patients coinfected with HIV and HCV are at risk for developing portal hypertension (PHT), hyper-dynamic circulation and pulmonary arterial hypertension (PAH). Data on the influence of antiviral therapy with pegylated interferon-α (PEG-IF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe189865773b53cdecdc8331bc7c1ba4
https://pubmed.ncbi.nlm.nih.gov/22948263